Substantial advancements have been made in our understanding of the complex replication cycle of, and immunopathology associated with HIV infection as well as the drugs used to treat the disease. The nucleoside reverse transcriptase inhibitors remain the cornerstones of current antiviral treatment modalities. Unfortunately, their long-term use often leads to adverse reactions and the emergence of virus mutants with decreased susceptibility to therapeutic agents. In addition to viral resistance, prolonged antiviral treatment may affect metabolic changes in the host cells that can diminish the efficacy of the treatment. Thus, both viral and cellular resistance mechanisms must be considered in the context of failing antiviral chemotherapy. This review article concerns the intracellular pharmacology of antiviral nucleoside analogues in human lymphoid cells and the possible impact of a newly identified nucleotide transporter on drug resistance.
References
1.
CarpenterC.C.J., FishlM.A., HammerS.M., HirschM.S., JacobsenD.M., KatzensteinD.A., MontanerJ.S., RichmanD.D., SaagM.S., SchooleyR.T., ThompsonM.A., VellaS., YeniP.G., & VolberdingP.A.Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society– USA Panel. Journal of the American Medical Association1998; 280: 78–86.
2.
WongJ.K., GunthardH.F., HavlirD.V., ZangZ.Q., HaaseA.T., IgnacioC.C., KwokS., EminiE., & RichmanD.D.Reduction of HIV-1 in blood and lymph nodes following potent anti-retroviral therapy and the virologic correlates of treatment failure. Proceedings of the National Academy of Sciences, USA1997; 94: 12574–12579.
3.
GulickR., MellorsJ., HavlirD., EronJ., GonzalezC., McMahonD., RichmanD., ValentineF., JonasL., MeibohmA., ChiouR., DeutschP., EminiE., & ChodakewitzJ.Potent and sustained release antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC).3rd Conference on Retroviruses and Opportunistic Infections, Washington, USA, January–February 1996. Abstract LB7.
4.
LangeJ., & RichmanD.The first blow is half the battle. Antiviral Therapy1997; 2: 132–133.
5.
D'AquilaR., JohnsonV., WellesS., JapourA.J., KuritzkesD.R., De GruttolaV., ReichelderferP.S., CoombsR.W., CrumpackerC.S., KahnJ.O., & RichmanD.D.Zidovudine resistance and HIV-1 disease progession during antiretroviral therapy. ACTG Protocol 116B/117 Team, the Virology Committee Resistance Working Group. Annals of Internal Medicine1995; 122: 401–408.
6.
JapourA.J., WellesS., D'AquilaR.T., JohnsonV.A., RichmanD.D., CoombsR.W., ReichelderferP.S., KahnJ.O., CrumpackerC.S., & KuritzkesD.R.Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. Journal of Infectious Diseases1995; 171: 1172–1179.
7.
KatlamaC., ValantinM.A., CalvezV., MatheronS., CoutelierA., DescampsD., LonguetC., DesaM., BonmarchandM., LancarR., AgutH., Brun-VezinetF., & CostagliolaD.ALTIS: a pilot open study of d4T/3TC in antiretroviral naive and experienced patients.4th Conference on Retroviruses and Opportunistic Infections, Washington, USA, January 1997. Abstract LB4.
8.
HavlirD.V., FriedlandG., PollardR., SmeatonL., SommadossiJ.P., & FoxL.Combination zidovudine and stavudine therapy versus other nucleosides: Report of two randomized trials (ACTG 290 and 298)5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 1998. Abstract 2.
9.
HoD.D., NeumannA.U., PerelsonA.S., ChenW., LeonardJ.M., & MarkowitzM.Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature1995; 373: 123–126.
10.
WeiX., GhoshS.K., TaylorM.E., JohnsonV.A., EminiV.A., DeutschP., LifsonJ.D., BohnoefferM.A., HahnB.H., SaagM.S., & ShawG.M.Viral dynamics in human immunodeficiency virus type 1 infection. Nature1995; 373: 117–122.
11.
GrossmanZ., FeinbergM., KuznetsovV., DimitrovD., & PaulW.HIV infection: how effective is drug combination treatment. Immunology Today1998; 19: 528–532.
12.
CinatiJ.Jr., CinatiJ., RabneauH., DoerrH.W., & WeberB.Failure of antiretroviral therapy: role of viral and cellular factors. Intervirology1994; 37: 307–314.
13.
SommadossiJ-P, ValantinM.A., ZhouX-J, XieM.Y., MooreJ., CalvezV., DesaM., & KatlamaC.Intracellular phosphorylation of stavudine (d4T) and 3TC correlates with their antiviral activity in naive and zidovudine experienced HIV-infected patients.5th Conference on Retroviruses and Opportunistic Infections, Washington, USA, February 1998. Abstract 262.
Foudraine NA HoetelmansR.M.W., LangeJ.M.A., de WolfF., van BenthemB.H., MaasJ.J., KeetI.P., & PortegiesP.Cerebrospinal fluid (CSF) HIV RNA and drug concentrations during treatment with lamivudine (3TC) in combination with zidovudine (AZT) or stavudine (D4T). Lancet1998; 351: 1547–1551.
17.
JohnsD.G.Pharmacology of antiretroviral nucleoside analogs. In Anti-HIV nucleosides: past, present and future. Edited by MitsuyaH.1997; pp. 23–50. Austin: RG Landes.
18.
WongJ.K., HezarehM., GunthardH.F., HavlirD.V., IgnacioC.C., SpinaC.A., & RichmanD.D.Recovery of replication competent HIV despite prolonged suppression of plasma viremia. Science1997; 278: 1291–1295.
19.
HoD.D.Toward HIV eradication or remission: the task ahead. Science1998; 280: 1866–1867.
20.
GottesmanM.M., & PastanI.Biochemistry of multidrug resistance mediated by the multidrug transporter. Annual Reviews in Biochemistry1993; 62: 385–427.
21.
ColeS.P., & DeeleyR.G.Multidrug resistance associated with over-expression of MRP. Cancer Treatment Research1997; 87: 39–62.
22.
HigginsC.F.ABC transporters: from microorganisms to man. Annual Reviews in Cell Biology1992; 8: 67–113.
23.
KimR.B., FrommM.F., WandelC., LeakeB., WoodA.J., RodenD.M., & WilkinsonG.R.The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation1999; 101: 289–294.
24.
LeeS.C., & GrabowskiB.A.HIV protease inhitors and the MDR1 multidrug transporter. Journal of Clinical Investigation1998; 101: 287–288.
25.
SrinivasR.V., MiddlemasD., FlynnP., & FridlandA.Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporters MDR1 and MRP1 but retain their antiviral efficacy in cell lines expressing these transporters. Antimicrobial Agents and Chemotherapy1998; 42: 3157–3162.
26.
LohoffM.S., PrechtlS., SommerF., RoellinghoffM., SchmittE., GradehandtG., RohwerP., StrideB.D., ColeS.P., & DeeleyR.G.A multidrug resistance protein (MRP)-like multitrans-membrane pump is highly expressed by resting murine T helper (Th) 2 cells but not Th1 cells and is induced to equal expression levels in Th1 and Th2 cells after mitogenic stimulation in vivo.Journal of Clinical Investigation1998; 101: 703–710.
27.
AntonelliG., TurriaziniO., CianfrigiaM., RivaE., DongG., FattorossiA., & DianzaniF.Resistance of HIV to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Research and Human Retroviruses1992; 8: 1839–1844.
28.
GollapudiS., & GuptaS.Human immunodeficiency virus–1 induced expression of P-glycoprotein (mdr-1). Biochemistry and Biophysics Research Communications1990; 171: 1002–1007.
29.
GuptaS., & GollapudiS.P-glycoprotein (mdr-1) in cells of the immune system: Its possible physiological role and alteration in aging and human immunodeficiency virus-1 (HIV) infection. Journal of Clinical Immunology1993; 13: 289–301.
30.
AndreanaA., AggarwalS., GollapudiD., WienD., TsuruoT., & GuptaS.Abnormal expression of a 170 kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Research and Human Retroviruses1996; 12: 1457–1462.
31.
LuciaM.B., CaudaR., LandayA.L., MalorniW., DonelliG., & OrtonaL.Transmembrane P-glycoprotein (p-gp/P-170) in HIV infection: Analysis of lymphocyte surface expression and drug unrealted function. AIDS Research and Human Retroviruses1995; 8: 893–901.
32.
PeterK., LalezariJ.P., & GambertoglioJ.G.Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay method. Journal of Pharmaceutical and Biomedical Analysis1996; 14: 491–499.
33.
RobbinsB.L., ConnellyM.C., MarshallD.R., SrinivasR.V., & FridlandA.A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Molecular Pharmacology1995; 47: 391–397.
34.
SchuetzJ.D., ConnellyM.C., SunD., PaibirS.G., FlynnP.M., SrinivasR.V., KumarA., & FridlandA.MRP4: a previously unidentified factor in resistance to nucleoside based antiviral drugs. Nature Medicine1999; 5: 1048–1051.
35.
HatseS., De ClercqE., & BalzariniJ.Enhanced 9-(2-phosphonylmethoxyethyl)adenine secretion by a specific indomethacin-sensitive efflux pump in a mutant 9-(2-phosphonylmethoxyethyl)adenine resistant human erythroleukemia K562 cell line. Molecular Pharmacology1998; 54: 907–917.
36.
YusaK., Oh-haraT., TsukaharaS., & TsuruoT.Human immunodeficiency virus type 1 induces 1-(-d-arabinofura-nosylcytosine resistance in human H9 cell line. Journal of Biological Chemistry1992; 267: 16848–16850.
37.
WuS., LiuX., SolorzanoM.M., KwockR., & AvramisV.I.Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5′-end of the human TK gene. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1995; 8: 1–9.
38.
LucarelliM., PallitiF., CarottiD., CianfrigliaM., SignorettiC., BozziA., & StromR.AZT-induced hypermethylation of human thymidine kinase gene in the absence of total DNA hypermethylation. FEBS Letters1996; 396: 323–326.
39.
AntonelliG., TurrizianiO., VerriA., NarcisoP., FerriF., D'OffiziG., & DianzaniF.Long-term exposure to zidovudine affects in vitro and in vivo the efficacy of phosphorylation of thymidine kinase levels in peripheral blood cells from HIV seropositive individuals: implications for zidovudine metabolism. AIDS Research and Human Retroviruses1996; 12: 223–228.
40.
JacobsonB., BrittonS., TornevikY., & ErikssonS.Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIV infected individuals. Biochemical Pharmacology1998; 56: 389–395.
RodmanJ.H., FlynnP.M., RobbinsB.L., JimenezE., BardeguezD., RodriguezJ., BlanchardS., & FridlandA.Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immnunodeficiency virus type 1 infected women and newborn infants. Journal of Infectious Diseases1999; 180: 1844–1850.
43.
BackD.J., HoggardP.G., GibbonsS.E., LloydJ., KhooS.H., WilkinsE.G., MerryC., & BarryM.G.Zidovudine (ZDV) phosphorylation determined at intervals over 12 months in naive and experienced HIV+ patients.5th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, February 1998. Abstract LB10.
